Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 3Thoracic 2Plasma cell 2Gynecologic 2Genitourinary 2Gastrointestinal 2Breast 2Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Ovarian Neoplasms 106Fallopian Tube Neoplasms 48Carcinoma, Ovarian Epithelial 31Uterine Cervical Neoplasms 28Pancreatic Neoplasms 13Endometrial Neoplasms 13Neoplasms 10Colorectal Neoplasms 10Carcinoma, Non-Small-Cell Lung 10Breast Neoplasms 10Recurrence 7Prostatic Neoplasms 7Neoplasm Metastasis 7Lung Neoplasms 7Triple Negative Breast Neoplasms 6Stomach Neoplasms 6Sarcoma 6Urinary Bladder Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Peritoneal Neoplasms 5Cholangiocarcinoma 5Small Cell Lung Carcinoma 4Melanoma 4Head and Neck Neoplasms 4Esophageal Neoplasms 4Colonic Neoplasms 4Vulvar Neoplasms 3Uterine Neoplasms 3Multiple Myeloma 3Carcinoma 3

Interventions

Flow Cytometry 5Therapeutics 3Psychiatric Rehabilitation 3Methylprednisolone 3Immunologic Techniques 3Amplified Fragment Length Polymorphism Analysis 3Prednisone 2Polymerase Chain Reaction 2Ondansetron 2In Situ Hybridization, Fluorescence 2Immunoenzyme Techniques 2Gemcitabine 2Dexamethasone 2Calcium Dobesilate 2Aprepitant 2Analgesia 2Alemtuzumab 2sargramostim 1ruxolitinib 1rucaparib 1pemigatinib 1pembrolizumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1aldesleukin 1abiraterone 1Vorinostat 1Voriconazole 1Valacyclovir 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × Gemcitabine × Gynecologic × Clear all
NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Incyte Corporation

Phase 1/2 Terminated
201 enrolled 71 charts
BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡